Manufacture of medicinal aerosol canisters

Patent metadata

Field	Value
Publication number	US-9694149-B2
Application number	US-201214352113-A
Country	US
Kind code	B2
Filing date	Oct 18, 2012
Priority date	Oct 21, 2011
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

The present invention relates to methods of making medicinal aerosol canisters ( 10 ), in particular metered dose canisters ( 10 ), comprising aerosol formulation comprising medicament particles suspended in liquid propellant, for example for delivery by pulmonary or nasal inhalation as well as medicinal dispensers ( 100 ) including such canisters ( 10 ), such as metered dose medicinal dispenser in particular pressurized metered dose inhalers, wherein the liquid propellant in some embodiments contains HFA 134a and/or HFA 227, and the propellant component is subjected to one or more ultrasonic probes.

First claim

The invention claimed is:

1. A method of manufacturing medicinal aerosol canisters containing a medicinal formulation comprising particulate drug dispersed in liquefied HFA 134a and/or HFA 227 propellant, wherein the targeted number of canisters to be filled is greater than 500, the method comprising the steps:
(a) providing a mixture comprising a particulate drug and liquefied HFA 134a and/or HFA 227 propellant and, optionally, other non-HFA 134a/HFA 227-propellant component or components;
either simultaneously or subsequently to said providing (step a),
(b) subjecting said mixture to one or more powered ultrasonic probes, said one or more probes being submersed in said mixture, while agitating said mixture;
subsequently to said steps of providing and subjecting (steps a and b),
(c) filling treated mixture into aerosol containers followed by attaching a valve to each filled container (cold filling) resulting in a filled canister or alternatively filling treated mixture into aerosol containers through a valve pre-attached onto each container (pressure filling) resulting in a filled canister, where said mixture is subjected to at least a total of 200 applied kilowatts times seconds per liter (kW·s/liter).

2. A method according to claim 1 , wherein said one or more powered, submersed ultrasonic probes are powered continuously.

3. A method according to claim 1 , wherein the steps of providing and subjecting (steps a and b) comprise the operations of (i) adding particulate drug, liquefied HFA 134a and/or HFA 227 propellant and, if used, other non-HFA 134a/HFA 227-propellant component or components into a vessel, wherein said one or more powered, submersed ultrasonic probes are located in said vessel.

4. A method according to claim 3 , wherein the mixture is being mixed in said vessel.

5. A method according to claim 1 , wherein the steps of providing and subjecting (steps a and b) comprise the operations of (i) adding particulate drug, liquefied HFA 134a and/or HFA 227 propellant and, if used, other non-HFA 134a/HFA 227-propellant component or components into a vessel; (ii) circulating the mixture out of the vessel and back into the vessel through a re-circulation loop; and wherein said one or more powered, submersed ultrasonic probes are located in the re-circulation loop or in the vessel or, if applicable both.

6. A method according to claim 1 , wherein the method includes subjecting said mixture to two or more powered, submersed ultrasonic probes.

7. A method according to claim 1 , wherein the step of filling (c) comprises the operations of (i) transferring the treated mixture to a second vessel in a filling line; (ii) circulating the treated mixture out of the second vessel and back into the second vessel through a second re-circulation loop in the filling line; and (iii) delivering from the filling line via a filling head a metered aliquot of treated mixture into the aerosol container.

8. A method according to claim 7 , wherein the step of filling (step c) comprises subjecting said treated mixture to one or more powered ultrasonic probes, while agitating said treated mixture, said one or more probes being submersed in said treated mixture and located in the re-circulation loop of the filling line or in the filling vessel of the filling line or, if applicable, both.

9. A method according to claim 1 , wherein in step of providing (step a), the amounts of particulate drug, liquefied HFA 134a and/or HFA 227, and, if used, other component(s) are equal to that amount deemed required for selected, targeted number of canisters to be filled.

10. A method according to claim 1 , wherein in the step of providing (step a) the amount of particulate drug is equal to that amount deemed required for selected, targeted number of canisters to be filled, and wherein the amount of liquefied HFA 134a and/or HFA 227 propellant is less than that amount deemed required for selected, targeted number of canisters to be filled and, if used, other component(s) are equal to or less than that amount deemed required for selected, targeted number of canisters to be filled; and wherein the method comprises a further step prior to the step of filling (step c) and after the steps of providing and subjecting (step a and b), said further step comprising combining liquefied HFA 134a and/or HFA 227 propellant and, if applicable, other component(s) with the treated mixture such that amount of propellant and other component(s), if used, are equal to those amount(s) deemed required for selected, targeted number of canisters to be filled.

11. A method according to claim 1 , wherein the drug is selected from group consisting of an anti-inflammatory, anti-allergic, anti-asthmatic, anti-histamine, anti-cholinergic agent, anorectic, anti-depressant, anti-hypertensive agents anti-neoplastic agent, anti-tussive , anti-anginal, anti-infective, anti-migraine drug, anti-peptic, dopaminergic agent, analgesic, beta-adrenergic blocking agent, cardiovascular drug, hypoglaecemic, immunomodulator, lung surfactant, prostaglandin, sympathomimetic, tranquilizer, steroid, vitamin, sex hormone, vaccine, therapeutic sense or anti-sense nucleic acid, other therapeutic protein and other therapeutic peptide, and mixtures thereof.

12. A method according to claim 1 , wherein the valve is a metered dose valve.

13. A medicinal dispenser comprising a medicinal aerosol canister manufactured according to claim 1 .

14. A dispenser according to claim 13 , wherein the dispenser is a metered dose medicinal dispenser.

15. A dispenser according to claim 14 , wherein the metered dose medicinal dispenser is a pressurized metered dose inhaler.

16. A method according to claim 1 , wherein the targeted number of canisters to be filled is 2000 or more.

17. A method according to claim 1 , wherein the targeted number of canisters to be filled is 5000 or more.

18. A method according to claim 1 , wherein said one or more powered, submersed ultrasonic probes are powered non-continuously.

19. A method according to claim 1 , wherein one or more powered, submersed ultrasonic probes are elongate.

Assignees

• 3M Innovative Properties Co

Inventors

• Jinks Philip A
• Blatchford Christopher G

Classifications

• F04C2270/0421

  Controlled or regulated · CPC title

• B65D83/303

  using extension tubes located in or at the nozzle outlets · CPC title

• A61M2207/00

  Methods of manufacture, assembly or production · CPC title

• A61M2207/10

  Device therefor · CPC title

• A61M15/009 Primary

  using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08) · CPC title